The Motley Fool··Jonathan PoncianoRTW's $116M Cogent Bet Amplifies Biotech Rally Ahead of Key FDA Decision
RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.
COGTFDA approvalinstitutional investment